Abstract:
Background: Hepatitis delta virus (HDV) is a highly pathogenic virus, and causes rapid disease progression from
fulminant hepatitis (FH) to development of hepatocellular carcinoma (HCC) in patients co-infected with hepatitis B
virus (HBV). However, its exact global burden of HBV-HDV co-infections remains largely obscure, particularly in
sub-Saharan Africa. The objective of this study was to determine the prevalence of anti-hepatitis delta virus (anti-
HDV) in hepatitis B virus surface antigen (HBsAg)-positive blood donors from Kenya.
Methods: A total of 239 HBsAg-positive serum samples, obtained from healthy Kenyan blood donors from June
2014 to November 2017 were analyzed in this cross-sectional study. ELISA was done using the International
Immunodiagnostics HDV Ab EIA kit, according to the instructions of the manufacturer, for anti-HDV
immunoglobulin G (IgG) determination.
Results: Of the 239 HBsAg-positive blood donors, 187 (78.24%) were male, and 52 (21.76%) were female. The
average age of the study participants was 24.11 years. Serological analysis revealed that 3/239 (1.26%) study
participants were HDV seropositive.
Conclusions: Our data suggest that HDV infection is rare among blood donors in Kenya, with anti-HDV positivity
rates being relatively lower compared to other countries. Nonetheless, ongoing surveillance is essential to track any
potential changes in prevalence over time.
